Preimplantation Genetic Testing Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032

The global preimplantation genetic testing market size was estimated to be US$ 504 million in 2021 and is expected to grow at a CAGR of 9% between 2023 to 2032.

Preimplantation genetic testing or preimplantation genetic diagnosis is a process for earlier detection of genetic or developmental defects that may be present in embryos. This method is specifically used for embryos generated through in vitro fertilization (IVF) technique.

Preimplantation genetic testing has become a necessary and most sought-after way to detect such defects before implementing further pregnancy procedures. The likelihood of safe and healthy birth is ensured by actively selecting defect-free IVF-derived embryos from a larger set. Preimplantation genetic testing, therefore, helps in preventing hereditary disorders to pass down from parents to the child and also prevents any developmental defects present in embryos to proliferate.

IVF procedure consists of several steps which include a collection of eggs from egg donors, fertilization in test tubes, screening of embryo formation, selecting viable embryos, and implantation in the uterus of the mother. Within this procedure, preimplantation genetic testing is done post-fertilization and before selecting the embryo for implantation. All the embryos that are deemed healthy are frozen and stored for further implantation process whereas unfit embryos are destroyed. Preimplantation genetic testing can also be used for the determination of gender or other characteristics of the embryo.

The IVF and artificial insemination procedures, even though being perfected, have a significant chance of failure, stillbirth, or malformations. Early detection methods have therefore become necessary and are often sought after by patients and clinicians involved in artificial insemination methods. This ensures no malformations or health difficulties are present in babies if they are conceived.  Preimplantation genetic testing has been successfully employed for detecting cystic fibrosis, congenital diseases, thalassemia as well as many other diseases.

Several governments and NGOs promote the use of Pre-implantation genetic testing because of the obvious benefits they provide. This technique is especially useful in cases where one or both parents have known genetic defects. Preimplantation genetic testing is mostly done in tandem with the genetic screening of parents or donors ensuring genetic compatibility as well.

Factors enabling the growth of the preimplantation genetic testing market:

The preimplantation genetic testing market is experiencing increased demand due to increased usage of IVF services, rising demand for better health screening, and a higher rate of income for expecting parents. The rise in demand for such services is also supported by technological advances in genetics, bioinformatics, big data processing, and diagnostic tools. This growth is expected to be further enhanced by medical research, upscaling of genetic testing processes, and increasing knowledge of the human genome.

dditionally, welcoming approaches from governmental and regulatory bodies regarding diagnostic screening, and public outlook towards genetic testing. These drivers are enabling increased investment and operations by big pharmaceutical companies toward preimplantation genetic testing.

According to several statistics, many children especially those born through IVF techniques have increased chances of congenital birth defects. Point mutations, repeat defects, and mitochondrial defects can be detected through preimplantation genetic testing techniques. Because carriers of genetic defects, single gene donors, and older couples seeking pregnancy are prone to defective childbirths and this benefits the most it. 

Hurdles faced by the preimplantation genetic testing sector:

Even though the usage of preimplantation testing in particular and genetic determination tests, in general, has negative connotations, it is still seen increasing in the past decade. Certain aspects of preimplantation genetic techniques enable ethically challenging aspects like gender detection, biased expectations, and genetic engineering possibilities and therefore are seeing regulatory hurdles in some countries.

The diagnosis based on genetics in itself needs refinement as certain disorders are not yet fully understood and thus, not detectable through preimplantation genetic diagnosis. Public perception is still inclined towards traditional methods of conceiving which do not come under the ambit of IVF-based preimplantation methods. It is expected that a new surge for preimplantation genetic testing will come once these hurdles are clear. A new field of in-vivo embryo testing that utilizes genetic tools similar to preimplantation genetic diagnosis will emerge. 

Current and prospects:

The current market for preimplantation genetic testing is particularly based in North America and western Europe. These regions are expected to drive the market forward in the coming years. The expected growth will be driven by couples seeking late pregnancies, the curiosity of knowing pre-birth conditions, and lower costs due to the larger scale of the economy in this sector. North American market is expected to see continued growth in the preimplantation genetic testing market.

The emerging market of Asia-Pacific will also see an uptick in the use of preimplantation genetic services correlating with the increased adoption of IVF and genetic diagnosis techniques. Growing access to advanced healthcare and increased disposable income are turning the Asia-Pacific region into a hotbed for this market. The overall population and development of economies will ensure a faster growth rate for the preimplantation genetic testing market in countries like China, Japan, the Philippines, and India once adoption occurs.

Companies that are currently leading the preimplantation genetic testing market are Illumina, Inc., Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc., Oxford Gene Technology, Yikon Genomics, and SciGene Corporations.

Global Preimplantation Genetic Testing Market Segmentation:

By Types

• Preimplantation Genetic Testing
• Preimplantation Genetic diagnosis

By Technology 

• Next-Generation Sequencing
• Comparative Genomic Hybridization
• Single-Nucleotide Polymorphism
• Validation Biomarkers
• Fluorescence in Situ Hybridization
• Polymerase Chain Reaction

By Application    

• Single Gene Disorders 
• X-Linked Disorders         
• Aneuploidy
• Structural Chromosomal Abnormalities
• HLA Typing

By Product and Service  

• Instruments                             
• Reagents and Consumables
• Software and Services

By End-users

• Hospitals, Diagnostic Labs, and Service Providers                 
• Maternity Centers & Fertility Clinics
• Research Laboratories & Academic Institutes

By Geography

• North America
• United States
• Canada
• Rest of North America
• Europe
• Germany
• United Kingdom
• Italy
• France
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• India
• China
• Australia
• Rest of Asia Pacific
• Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of the Middle East & Africa
• South America
• Brazil
• Rest of South America